Samuel Cytryn

May 18, 2024 | hmpgloballearningnetwork.com | Samuel Cytryn

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Samuel Cytryn, MD, Memorial Sloan Kettering Cancer Center, New York, New York, discussed first-line use of claudin-18.2 inhibitors for the treatment of patients with gastroesophageal cancers. Transcript: My name is Sam Cytryn, I'm an assistant attending GI oncologist at Memorial Sloan Kettering Cancer Center.

Mar 21, 2024 | jnm.snmjournals.org | Samuel Cytryn |Neeta Pandit-Taskar |Melissa Lumish |Steven B. Maron

MATERIALS AND METHODSThis was a single-institution prospective pilot open-label microdose PET evaluating the PD-L1–targeting radiotracer 18F-BMS-986229 with PET imaging in 10 patients with GEC between February 3, 2020 and February 2, 2022. Ten (100%) patients had adenocarcinoma, 7 (70%) had metastatic disease, and 3 (30%) had received prior treatment at the time of PD-L1 PET imaging, including 2 with PD-1 inhibitors (Table 1). The median PD-L1 CPS was 10 (interquartile range, 5–20).

Sep 1, 2023 | thelancet.com | Samuel Cytryn |Ryan H. Moy |Darren Cowzer |Joanne F. Chou

Research in contextEvidence before this studyWe searched PubMed for published studies from database inception until April 1, 2023, using the search terms (“gastric cancer” OR “gastroesophageal cancer” OR “esophageal cancer”) AND (“regorafenib” OR “PD-1 inhibitor” OR “PD-L1 inhibitor”). The search was restricted to clinical trials with no language restrictions.